PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06345599
• Other study ID #: LK2023100
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 1, 2024
• Est. completion date: January 10, 2027

Study information

• Verified date: March 2024
• Source: Second Affiliated Hospital of Soochow University
• Contact: Wei Chen, Doctor
• Phone: 18626205529
• Email: trybest1971[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study).The main question it aims to answer is to investigate the safety and efficacy of the PRaG treatment modality combined with chemotherapy neoadjuvant therapy for locally advanced pancreatic cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 66
• Est. completion date: January 10, 2027
• Est. primary completion date: January 10, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age = 18 = 75 years;no gender limitations

• Histopathologically and/or cytologically confirmed ductal adenocarcinoma of the pancreas, the patient has fresh pathological tissue and the tumour is located in the head and neck or body of the pancreas

• Locally advanced pancreatic cancer, borderline resectable or unresectable, without metastases.

• Life expectancy >= 3 months.

• ECOG score 0-1.

• Have at least 1 measurable lesion according to RECIST 1.1 criteria.

• No prior treatment with abdominal radiotherapy, chemotherapy and PD-1/PD-L1 antibody.

• Adequate organs functions as defined by the following laboratory values (completed within 14 days prior to registration): (1) haemoglobin >= 90 g/L (no blood transfusion within 14 days); (2) neutrophil count > 1.5x10^9/L; (3) platelet count >= 100x10^9/L; (4) total bilirubin <= 1.5xULN (upper limit of normal); (5) blood glutamic transferase (ALT) or blood glutamic transferase (AST) <= 2.5xULN (6) endogenous creatinine clearance >= 60 ml/min (Cockcroft's AST). (ALT) or blood albumin transaminase (AST) <= 2.5xULN; (6) endogenous creatinine clearance >= 60 ml/min (Cockcroft-Gault formula); (7) cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) >= 50%. (8) International normalised ratio (INR) of prothrombin time = 1.5 and partial thromboplastin time (APTT) = 1.5 times the upper limit of normal in patients who have not received anticoagulation. Patients receiving full or parenteral anticoagulant therapy may enter a clinical trial as long as the dose of anticoagulant has been stable for at least 2 weeks prior to entry into the clinical study and the results of coagulation assays are within the limits of local therapy.

• No congestive heart failure, unstable angina, unstable arrhythmia in the last 6 months.

• No previous severe haematopoietic, cardiac, pulmonary, hepatic or renal abnormalities or immunodeficiencies.

• Patient must be able to understand the potential risks and benefits associated with this study. Patient able to give informed consent and would likely to comply with the study parameters.

Exclusion Criteria:

• Pregnant or breastfeeding women

• Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and cervical cancer in situ.

• Patients with a history of uncontrolled epilepsy, central nervous system disease or psychiatric disorders whose clinical severity, in the judgement of the investigator, may prevent the signing of informed consent or affect the patient's adherence to drug therapy.

• Severe heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmia requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months.

• Organ transplants requiring immunosuppressive therapy

• Active infection or, in the investigator's judgement, significant haematological, renal, metabolic, gastrointestinal, endocrine function or metabolic disorders, or other serious uncontrolled concomitant disease

• Allergy to any of the study drug ingredients

• History of immunodeficiency, including HIV-positive or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or other immune-related diseases requiring long-term oral hormone therapy

• During acute or chronic tuberculosis infection (patients with a positive T-spot test and suspicious tuberculosis foci on chest radiographs).

• Other conditions considered by the investigator to be unsuitable for enrolment.

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Intervention

Radiation:
• Radiotherapy
This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.

Drug:
• Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)?Cadumilimab
GM-CSF treatment: GM-CSF 200µg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
• Chemotherapy:Albumin-bound paclitaxel?Gemcitabine
Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Soochow University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	From the beginning of treatment, record the treatment-related toxic reactions that occur in patients.	36 months
Primary	Serious adverse events	From the start of treatment, record any severe adverse reactions that occur in the patient.	36 months
Primary	1-year overall survival	Record the 1-year overall survival rate of patients after receiving treatment	The 1-year overall survival rate of patients after receiving treatment
Secondary	Objective response rate	The lesions were evaluated according to the RECIST1.1 standard, and the proportion of patients with the best treatment response of CR and PR after treatment to the total number of evaluable cases was calculated.	36 months
Secondary	Disease control rate	The lesions were evaluated according to the RECIST1.1 standard, and the proportion of patients with optimal treatment response of CR, PR, and SD after treatment was calculated based on the total number of evaluable cases.	36 months
Secondary	Overall survival	The time from the first day of enrollment to the occurrence of death due to any reason. Patients who are still alive at the time of analysis will use the date of their last contact as the deadline.	36 months
Secondary	R0 resection rate	The tumor was completely removed during surgery, and the resection margin was negative under microscopic observation.	36 months
Secondary	Progression free survival	The time between the start of treatment and the observation of disease progression or death for any reason. Patients who are still alive at the time of analysis will use the date of their last contact as the cutoff date.	36 months